Close Menu

Janssen

The companies will work together to develop a next-generation sequencing-based companion diagnostic for an undisclosed cancer therapy.

The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.

Resolution is developing its liquid biopsy assay as a companion diagnostic for niraparib in metastatic castration-resistant prostate cancer.

Qiagen's test is intended to identify advanced bladder cancer patients with alterations in FGFR3 or FGFR2 genes and who are likely to respond to erdafitinib.

VALUE-Dx involves six IVD companies and is being heralded by participants as an opportunity for competitors to work together to improve test adoption.

The companies will evaluate the performance of Proteomics International's PromarkerD test for predicting decline in kidney function and drug response.

Saladax will have the patent rights to Janssen Pharmaceutica's tests that determine drug levels in patients undergoing treatment with antipsychotic drugs.

The company is planning to submit the drug and a companion diagnostic that can identify patients with FGFR alterations with the FDA in the second half of 2018.

GenomeDx will test its Decipher GRID database of cancer genomic profiles with samples from Janssen-run prostate cancer clinical trials.

The partners will develop an amyloid β 42/40 ratio assay to identify patients who may benefit from treatment with Janssen's drug called atabecestat.

Pages